Stay updated with breaking news from Clinical Research Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The use of olaparib as a monotherapy or in combination with cediranib did not provide a statistically significance overall survival (OS) benefit compared with standard of care platinum-based chemotherapy in patients with recurrent, platinum-sensitive ovarian cancer.
The use of olaparib as a monotherapy or in combination with cediranib did not provide a statistically significance overall survival benefit compared with standard-of-care platinum-based chemotherapy in patients with recurrent, platinum-sensitive ovarian cancer.
/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
The doctor, a scientist at Spain’s National Oncological Research Center, has just launched a spin-off on personalized oncology nutrition to help optimize the results of therapies and reduce toxicities
CORAL GABLES - Relmada Therapeutics, Inc. , a late-stage biotechnology company addressing diseases of the central nervous system , today announced that it will present three posters at the upcoming...